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Estimated glomerular filtration rate (eGFR) was used for
analysis of kidney disease prevalence in the United States.
The study investigated on prevalence, associated disorders,
and kidney disease awareness in an Italian population
sample. Data were collected on serum creatinine, other
laboratory indices, blood pressure, and medical history in the
Gubbio Population Study (n¼ 4574, both sexes, ages 18–95
years). Analyses were carried out on eGFR (equation of
Modification Diet in Renal Disease study), disorders
potentially secondary to kidney dysfunction (hypertension,
high serum uric acid, high serum phosphorus/low serum
calcium, high serum potassium, cardiovascular disease,
anemia), and kidney disease awareness. The prevalence of
eGFRo60 ml/min 1.73 m2 increased with age in both sexes
(from o1% for ages 18–24 years to 430% for ages X75
years, Po0.001). In the group with eGFR o60 ml/
min 1.73 m2, number of disorders secondary to kidney
dysfunction was X2 in the majority of persons, was higher
than in persons with eGFR X60 ml/min 1.73 m2 (Po0.001),
and was inversely related to eGFR (Po0.001). The prevalence
of reported kidney disease was 3.3% in the group with eGFR
o60 ml/min 1.73 m2 and directly related to serum
creatinine and number of disorders secondary to kidney
dysfunction (Po0.001). Low kidney function is frequent in
the older population and is associated with disorders typical
of kidney disease. Persons with low kidney function are rarely
aware of kidney disease unless of very high serum creatinine
or presence of many disorders typical of kidney disease.
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Chronic kidney disease is a risk factor for the development of
severe complications, including other morbidities, progres-
sion toward kidney failure, and increased mortality.1
Controlled clinical trials show that the treatment of early
stages of chronic kidney disease slows down the rate of
progression of kidney damage and has a beneficial effect on
complications.2,3 Chronic kidney disease is poorly treated
and often underdiagnosed,4–6 also because the early stages of
the disease are at times without overt clinical presentation.7
The National Kidney Foundation suggests that early stages of
chronic kidney disease can be detected and diagnosed with
the help of the estimated glomerular filtration rate (eGFR) or
the predicted creatinine clearance, that is, indices of
glomerular filtration rate (GFR) that are calculable with the
use of serum creatinine and other variables by the equation of
the Modification Diet in Renal Disease study (MDRD
equation) and/or the Cockcroft–Gault equation, respectively.1
Estimates on the prevalence of low kidney function were
conflicting in two previous studies in the US population,8,9
and were questioned by some authors.10,11 These previous
studies reported limited information on complications of
kidney disease. Thus, the present study was designed to
further investigate on the prevalence of low kidney function
in the population focusing analyses also on disorders
potentially secondary to kidney disease and other related
variables.
RESULTS
Descriptive statistics
A total of 4680 persons were with age X18 years in the
Gubbio population sample. The cohort for the present study
is made of 4574 persons as 106 persons (2.3%) were excluded
for missing data. Table 1 reports descriptive statistics. Age
range (min–max) was 18–91 in men and 18–95 in women.
The difference between the two eGFR values calculated for
women was 13.4% as expected per the difference between the
two factors used for calculation (0.841/0.742¼ 1.134).
Urinary creatinine of the Gubbio population was not
significantly different from urinary creatinine of the separate
group used for analyses on the accuracy of eGFR (P40.3).
Non-normalized serum total Ca correlated with serum total
protein in men and women (R¼ 0.145 and 0.163, Po0.001).
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Normalized serum total Ca (mg/100 ml) averaged 9.3070.56
in men and 9.3470.61 in women. No person reported
treatment with erythropoietin. Data for urinary albumin
were not included in Table 1 as it was available only for ages
45–64 years. Men had higher values than women for mean
urinary albumin (15.9783.1 and 10.6733.5 mg/min) and for
the prevalence of elevated urinary albumin (6.6 and 3.0%).
Prevalence of eGFR o60 ml/min 1.73 m2
The prevalence of eGFR o60 ml/min 1.73 m2 increased
with age in both sexes (Table 2). Age-adjusted estimates of
prevalence of eGFR o60 ml/min 1.73 m2 in the adult
Italian population were 5.7% for men (n¼ 1.29 million, 95%
confidence interval (CI)¼ 1.07/1.52) and 6.2% for women
(n¼ 1.53 million, 95% CI¼ 1.31/1.78). The prevalence of
eGFR o60 ml/min 1.73 m2 in women was 16.3% with the
use of eGFR by the original MDRD equation (2.8 times
higher than with the use of eGFR by lab-specific factor,
Po0.001) and increased from 0.4% for ages 18–24 years to
57.4% for ages 75 years and over.
eGFR o60 ml/min 1.73 m2 and creatinine
In comparison to persons with eGFRX60 ml/min 1.73 m2,
persons with eGFR o60 ml/min 1.73 m2 had higher serum
creatinine and similar urinary creatinine (Figure 1). Serum
creatinine of women defined with eGFR o60 ml/min
 1.73 m2 by original MDRD equation (not shown in
Figure 1) was lower than serum creatinine of women defined
with eGFRo60 ml/min 1.73 m2 by lab-specific factor (mg/
100 ml, mean¼ 1.125 and 1.275, 95% CI¼ 1.103/1.146 and
1.225/1.323).
eGFR o60 ml/min 1.73 m2 and associated disorders
Disorders potentially secondary to kidney dysfunction were
analyzed without and with age adjustment to control for the
confounding of age that correlated with eGFR o60 ml/
Table 1 | Descriptive statistics
Men
(n=2083)
Women
(n=2491)
Age (years) 40.4717.6 50.6717.6
With ages (n (%))
18–24 222 (10.7%) 232 (9.3%)
25–34 331 (15.9%) 325 (13.0%)
35–44 316 (15.2%) 364 (14.6%)
45–54 382 (18.3%) 460 (18.5%)
55–64 371 (17.8%) 485 (19.5%)
65–74 313 (15.0%) 381 (15.3%)
75 and over 148 (7.1%) 244 (9.8%)
With regular menses (n (%)) — 1171 (47.0%)
Serum creatinine (mg/100 ml) 1.0870.16 0.9070.16
eGFR (ml/min 1.73 m2) 81.3715.6 73.7715.5a
83.6717.6b
Urinary creatinine (mg/min) 1.22970.437 0.81770.286
Serum uric acid (mg/100 ml) 5.3171.31 3.9271.20
Serum phosphorus (mg/100 ml) 3.2770.65 3.4670.57
Serum total calcium (mg/100 ml) 9.4170.30 9.3770.31
Serum total protein (g/100 ml) 7.1070.40 7.0570.43
Serum potassium (mmol/l) 4.1870.36 4.0970.37
Hemoglobin (g/100 ml) 15.471.1 13.771.1
Blood pressure status
Systolic pressure (mm Hg) 127718 127721
Diastolic pressure (mm Hg) 75711 74711
On antihypertensive drugs (n (%)) 310 (14.9%) 466 (18.7%)
Cardiovascular disease
Cerebrovascular disease (n (%)) 52 (2.5%) 67 (2.7%)
Coronary heart disease (n (%)) 80 (3.8%) 84 (3.4%)
Heart failure (n (%)) 45 (2.2%) 72 (2.9%)
Claudicatio intermittens (n (%)) 29 (1.4%) 17 (0.7%)
With reported kidney disease (n (%)) 25 (1.2%) 54 (2.2%)
eGFR, estimated glomerular filtration rate.
aBy the original MDRD equation.
bBy lab-specific factor.
Table 2 | Percent (%) and absolute (n) prevalence of eGFR
o60 ml/min 1.73 m2 by age and gender
Age (years)
Men Women
% n % n
18–24 0.0 0 0.4 1
25–34 0.0 0 0.6 2
35–44 0.6 2 0.3 1
45–54 2.6 10 1.3 6
55–64 7.3 27 5.4 26
65–74 15.0 47 11.0 42
75 and over 34.5 51 31.6 77
all ages 6.6 137 6.2 155
eGFR, estimated glomerular filtration rate.
Po0.001 for difference by age stratum (w2 analysis within column).
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Figure 1 | Means of urinary creatinine (upper panels) and serum
creatinine (lower panels) by age stratum in group with eGFR
o60 ml/min 1.73 m2 (closed symbols) compared to group with
eGFR X60 ml/min 1.73 m2 (open symbols) in men (left panels,
circles) and women (right panels, diamonds, eGFR calculated by
the lab-specific factor). Serum creatinine differed between groups
in men and women (Po0.001 by two-way analysis of variance).
Urinary creatinine did not significantly differ between groups in any
analysis. Symbols are omitted in some age strata for the group with
eGFR o60 ml/min 1.73 m2 because of low n (n per gender and age
stratum in Table 2).
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min 1.73 m2 (Table 2) and with most of these disorders in
both sexes (not shown). Data of Tables 3 and 4 show that
disorders potentially secondary to kidney dysfunction were
more prevalent (odds ratio 41) in group with eGFR
o60 ml/min 1.73 m2 than in group with eGFR X60 ml/
min 1.73 m2 in all analyses. In men (Table 3), findings were
significant or borderline significant for high serum uric acid,
anemia, hypertension, and cardiovascular disease without
and with age adjustment, high serum K only without age
adjustment, and high serum P/low serum Ca only with age
adjustment. In women with eGFR by lab-specific factor
(Table 4), findings were significant or borderline significant
for all disorders without and with age adjustment. Findings
in women were similar but less consistent with the use of
eGFR by original MDRD equation. Age-adjusted odds ratio
was 1.05 for hypertension (95% CI¼ 0.80/1.37), 2.29 for high
serum uric acid (1.68/3.13), 1.45 for high serum P/low serum
Ca (1.08/1.94), 1.34 for high serum K (0.89/2.03), 1.31 for
cardiovascular disease (0.93/1.85), and 1.30 for anemia (0.66/
2.53).
Table 3 | Disorders typical of kidney disease in whole cohort and in group with eGFRo60 ml/min 1.73 m2 compared to group
with eGFR X60 ml/min 1.73 m2: % prevalence and OR between groups without age adjustment (unadjusted) and with age
adjustment (adjusted)
Whole cohort
eGFR (ml/min 1.73 m2)
OR (95% CI)
(n=2083) (%) o60 (n=137) (%) X60 (n=1946) (%)
Hypertension 31.5 Unadjusted 67.9*** 29.0 5.18 (3.57/7.51)
Adjusted 44.0*** 30.7 1.63 (1.09/2.44)
High serum uric acid 10.8 Unadjusted 30.7*** 9.5 4.23 (2.86/6.28)
Adjusted 26.2*** 9.8 2.61 (1.70/4.00)
High serum P/low serum Ca 17.3 Unadjusted 18.2ns 17.2 1.07 (0.69/1.68)
Adjusted 25.6** 16.7 1.98 (1.22/3.21)
High serum K 9.0 Unadjusted 13.9* 8.6 1.70 (1.02/2.84)
Adjusted 10.1ns 8.9 1.06 (0.62/1.82)
Cardiovascular disease 8.8 Unadjusted 24.8*** 7.7 3.98 (2.61/6.07)
Adjusted 17.6*** 8.2 1.59 (1.01/1.52)
Anemia 0.5 Unadjusted 1.5^ 0.4 3.59 (0.76/17.01)
Adjusted 1.5^ 0.4 3.71 (0.62/22.23)
CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.
Men, ages 18–91 years.
nsNot significant, ^Po0.10, *Po0.05, **Po0.01, ***Po0.001 by w2 analysis or age-adjusted ANOVA.
Table 4 | Disorders typical of kidney disease in whole cohort and in group with eGFRo60 ml/min 1.73 m2 compared to group
with eGFR X60 ml/min 1.73 m2: % prevalence and OR between groups without age adjustment (unadjusted) and with age
adjustment (adjusted)
Whole cohort
eGFR (ml/min 1.73 m2)
OR (95% CI)
(n=2491) (%) o60 (n=155) (%) X60 (n=2336) (%)
Hypertension 35.2 Unadjusted 74.8*** 32.6 6.16 (4.24/8.94)
Adjusted 43.2^ 34.7 1.28 (0.83/1.96)
High serum uric acid 10.0 Unadjusted 41.9*** 7.9 8.40 (5.90/11.95)
Adjusted 34.8*** 8.4 3.54 (2.40/5.20)
High serum P/low serum Ca 18.1 Unadjusted 24.5* 17.7 1.51 (1.03/2.21)
Adjusted 26.8** 17.6 1.78 (1.19/2.69)
High serum K 6.1 Unadjusted 16.8*** 5.4 3.54 (2.24/5.59)
Adjusted 14.3** 5.6 2.23 (1.35/3.68)
Cardiovascular disease 8.3 Unadjusted 25.2*** 7.1 4.37 (2.94/6.49)
Adjusted 17.4*** 7.7 1.46 (0.94/2.25)
Anemia 2.5 Unadjusted 7.7*** 2.1 3.84 (2.00/7.37)
Adjusted 7.6*** 2.2 3.65 (1.75/7.64)
CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.
Women, ages 18–95 years, eGFR by lab-specific factor.
^Po0.10, *Po0.05, **Po0.01, ***Po0.001 by w2 analysis or age-adjusted ANOVA.
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The number of disorders present in each person (n
disorders/person) was calculated as a quantitative index of
disorders potentially secondary to kidney dysfunction
(theoretical range: min¼ 0; max¼ 6). The distribution of n
disorders/person differed between groups with and without
eGFR o60 ml/min 1.73 m2 in all analyses (not shown,
Po0.001). Persons with two or more disorders were much
more prevalent in the group with eGFR o60 ml/min
 1.73 m2 than with eGFR X60 ml/min 1.73 m2 among
men (50.4 and 16.4%, Po0.001) and women (61.3 and
16.9% for eGFR by lab-specific factor, Po0.001). In age-
adjusted analyses, the n disorders/person in the group with
eGFR o60 ml/min 1.73 m2 was linearly higher with
decreasing eGFR (Figure 2). In the group with eGFR
X60 ml/min 1.73 m2, the n disorders/person was not
linearly related to eGFR and with slightly high values only
for eGFR 60–79 ml/min 1.73 m2 (Figure 2). Findings in
women were similar but less consistent with the use of eGFR
by original MDRD equation. Women with two or more
disorders were 42.9% in the group with eGFR o60 ml/
min 1.73 m2 and 14.8% in the group with eGFR X60 ml/
min 1.73 m2 (Po0.001).
Elevated urinary albumin: Prevalence and associated dis-
orders
The prevalence of elevated urinary albumin (not included in
previous analyses because available only for ages 45–64 years)
was not related to age within the age range 45–64 years (not
shown, P40.7), and was not significantly different between
persons with eGFR o60 ml/min 1.73 m2 and persons with
eGFRX60 ml/min 1.73 m2 in any analysis (not shown,
P40.6 with and without age adjustment). The prevalence of
disorders potentially secondary to kidney dysfunction was
compared between groups with and without elevated urinary
albumin only among persons with eGFRX60 ml/min
 1.73 m2 to investigate on elevated urinary albumin
independent of eGFR reduction. Data in Table 5 show that
disorders potentially secondary to kidney dysfunction were
more prevalent in the group with elevated urinary albumin
than in the group without elevated urinary albumin only in
analyses for hypertension, high serum uric acid, and
cardiovascular disease (not significant in women), not in
analyses for high serum P/low serum Ca, high serum K, and
anemia. Findings were identical in age-adjusted analyses and
in analyses for women with the use of eGFR by original
MDRD equation (not shown).
Awareness and control of eGFRo60 ml/min 1.73 m2
In the group with eGFR o60 ml/min 1.73 m2, prevalence
of reported kidney disease was not associated with gender (in
men 5.8%, in women 3.9% for eGFR by lab-specific factor,
2.6% for eGFR by original MDRD equation, P40.7) or with
age (P40.6). In men and women combined together,
reported kidney disease was associated with eGFR (ml/
min 1.73 m2, 59–50¼ 2.1%, 49–40¼ 3.4%, o40¼ 23.1%,
Po0.001) and with the n disorders/person (0–1 dis-
order¼ 2.1%, 2–3 disorders¼ 3.4%, 4 or more dis-
orders¼ 10.5%, P¼ 0.025).
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Figure 2 | Age-adjusted means of n disorders/person by eGFR
strata in group with eGFR o60 ml/min 1.73 m2 (closed sym-
bols) and group with eGFRX60 ml/min 1.73 m2 (open symbols)
for men (circles) and women (diamonds, eGFR by lab-specific
factor). The n disorders/person differed among eGFR strata of men
and women in analyses for all strata (Po0.001 by analysis of
variance), analyses limited to strata with eGFR o60 ml/min 1.73 m2
(Po0.01), and analyses limited to strata with eGFR X60 ml/min
 1.73 m2 (Po0.001 for men and P¼ 0.038 for women).
Table 5 | Disorders typical of kidney disease in persons with eGFR X60 ml/min 1.73 m2 divided in group with and group
without elevated urinary albumin: % prevalence and OR between groups without age adjustment
Men Womena
With elevated
urinary albumin
(n=45) (%)
Without elevated
urinary albumin
(n=649) (%) OR (95% CI)
With elevated
urinary albumin
(n=27) (%)
Without elevated
urinary albumin
(n=863) (%) OR (95% CI)
Hypertension 75.6** 36.8 5.30 (2.64/10.66) 77.8** 38.6 5.57 (2.23/13.94)
High serum uric acid 24.4** 11.9 2.40 (1.17/4.94) 29.6** 8.5 4.56 (1.93/10.77)
High serum P/low serum Ca 8.9ns 11.6 0.75 (0.26/2.14) 7.4ns 16.8 0.40 (0.09/1.69)
High serum K 4.4ns 9.7 0.43 (0.10/1.83) 7.4ns 7.6 0.97 (0.22/4.17)
Cardiovascular disease 20.0* 9.9 2.29 (1.05/4.16) 11.1ns 6.4 1.84 (0.54/6.29)
Anemia 0.0ns 0.5 NC 0.0ns 2.0 NC
CI, confidence interval; eGFR, estimated glomerular filtration rate; NC, not calculable; OR, odds ratio.
Men and women, ages 45–64 years.
nsNot significant, *Po0.05, **Po0.001 by w2 analysis.
aeGFR by lab-specific factor.
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Hypertension treatment was more frequent in hyperten-
sives with eGFR o60 ml/min 1.73 m2 than hypertensives
with eGFR X60 ml/min 1.73 m2 among men (64.5 and
44.3%, Po0.001) and women (70.7 and 50.5% for eGFR by
lab-specific factor, Po0.001). Hypertension control was
slightly less frequent in hypertensives with eGFR o60 ml/
min 1.73 m2 than hypertensives with eGFR X60 ml/
min 1.73 m2 among men (45.0 and 52.0%, P¼ 0.330) and
women (32.9 and 36.5% for eGFR by lab-specific factor,
P¼ 0.545). Findings in women were similar for eGFR by
original MDRD equation (not shown).
DISCUSSION
The study reports population-based data on the prevalence of
low kidney function defined by the MDRD equation together
with information on associated disorders, awareness, and
control of kidney disease. In both sexes, the prevalence of low
kidney function varied exponentially from rates o1% for
ages 18–34 years up to rates 430% for ages X75 years.
Independent of sex and age, persons with low kidney
function had disorders typical of kidney disease. The number
of disorders was higher with decreasing eGFR. Awareness of
kidney disease was low and was associated with serum
creatinine and number of disorders. Last, hypertension
treatment was common in persons with low kidney function,
but not associated with better blood pressure control.
Several limitations could influence the results. First, the
MDRD equation was used without calibration of creatinine
assay with the MDRD lab.12 The use of the equation was
validated by analyses on the accuracy of eGFR as predictor of
true GFR in a group of persons with and without kidney
disease not belonging to the Gubbio population. The
different prevalence of kidney disease between the validation
group and the Gubbio population could affect the results, as
the MDRD equation tends to underestimate normal–high
true GFR.13,14 An additional eGFR value was calculated for
women by a lab-specific gender factor to control for the
underestimate of true GFR found in women under our
experimental conditions.13 Second, a major confounding of
creatinine generation was unlikely as urinary creatinine was
similar in the validation group compared to the Gubbio
population and, within the Gubbio population, in persons
with compared to persons without low kidney function.
Third, a single serum creatinine measure could have caused
misclassification. This error should not be large because data
for a subset of the population indicated a low variability over
time in serum creatinine. Misclassification owing to a single
measure could have occurred also for other variables as
urinary albumin,15 etc. Further limitations derive from the
cross-sectional design (limiting data extrapolation to chronic
and/or progressive kidney disease) and the absence of data
for various ethnic groups (limiting information to white
persons only). Finally, data from a single city could be poorly
representative, although end-stage renal disease is similarly
prevalent in the Gubbio area and in Italy (sex- and age-
adjusted data: 812/million, 95% CI¼ 751/873 and 845/
million, 95% CI¼ 837/852) (Italian Registry of Dialysis and
Transplantation. Report 2001, e-pub at http://www.sin-ridt.
org/sin-ridt/sin-ridt.org.htm by the Italian Society of
Nephrology).
The prevalence of low kidney function and its relation to
age in the Gubbio population are consistent with the data of
Coresh et al.,9 not with data of Clase et al.8 The high
prevalence in women with eGFR calculated by the original
MDRD equation reasonably reflected the inaccuracy of
MDRD equation in women in our study. The association of
low kidney function with disorders typical of kidney disease
extends the information of K/Dialysis Outcome Quality
Initiative7 and supports the view that eGFR is a reliable tool
for the detection of person with or at risk of kidney disease.1,9
eGFRo60 ml/min 1.73 m2 was consistently associated with
disorders typical of kidney disease, except for few analyses in
women with eGFR calculated by original MDRD equation,
that is, for analyses with more false definitions of low eGFR.
Hypertension was the most common disorder in low kidney
function for the interaction of several factors: a true
association between low kidney function and hypertension,
high hypertension prevalence in the whole population, and
the association of age with hypertension and low kidney
function. Another strong correlate was high serum uric acid, a
trait that is often neglected as a marker of low kidney
function. High serum P/low serum Ca, cardiovascular disease,
and anemia were less frequent but consistently associated with
low kidney function. The overall n disorders/person was
elevated in persons with low kidney function and linearly
higher with decreasing eGFR as in K/Dialysis Outcome
Quality Initiative non-adjusted data for another set of
variables.7 Among persons without low kidney function, the
n disorders/person was stably low for eGFR X80 ml/
min 1.73 m2 and tended to increase only for eGFR between
60 and 80 ml/min 1.73 m2. Thus, data suggested that the
definition of low kidney function could be at eGFR of 80 ml/
min 1.73 m2.16 In the subgroup with measured data, urinary
albumin was not associated with low eGFR and, among
disorders typical of kidney disease, was associated only with
hypertension, high serum uric acid, and cardiovascular
disease. Thus, elevated urinary albumin per se could point
to cardiovascular and metabolic alterations rather than to low
kidney function. Less than 6% of persons with low kidney
function reported a diagnosis of kidney disease. Such a low
awareness is not surprising in view of data reporting a
diagnosis of kidney disease in a small minority of hospitalized
patients with documented signs of kidney dysfunction.6 The
correlation of kidney disease awareness with eGFR and
number of associated disorders indicated that the few persons
aware of kidney disease were with severe eGFR reduction and/
or with several associated disorders. The control of kidney
disease was also low. The majority of hypertensives with low
kidney function reported antihypertensive treatment as for US
data.5,17 Nevertheless, blood pressure was uncontrolled even
with the use of targets higher than those suggested for kidney
disease.1
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In summary, the study reports the first systematic analysis
on the epidemiology of low kidney function in an Italian
population sample together with information on disorders
potentially secondary to kidney disease and other related
variables. Data confirm that low eGFR is not rare in middle-
aged adults and is highly prevalent in older individuals. The
association of low eGFR with disorders typical of kidney
disease supports the idea that predicted indices of GFR are a
useful tool for the identification of persons with or at risk of
kidney disease. Also, results on awareness, treatment, and
control suggest the need of worldwide population-based
strategies for the prevention of kidney disease and its
complications.
MATERIALS AND METHODS
The Gubbio Study is a population-based investigation ongoing in
the city of Gubbio in central Italy.18 Activities were approved by the
Local Institutional Review Committee and included an informed
consent by participants. Previous papers reported information on
responders and non-responders, time of examinations, and
similarities between the Gubbio population study sample and the
Italian population.18,19 The second examination of the Gubbio
Study included the collection of urine (timed overnight collection)
and blood (early morning venous samples under fasting condition)
for laboratory determinations, the administration of questionnaires,
and the measurement of blood pressure.20 All procedures were in
accordance with institutional guidelines.
Measurements and questionnaires
Laboratory determinations were carried out by automated proce-
dures and included urinary creatinine, blood hemoglobin, and
serum concentrations of creatinine, uric acid, potassium (K),
phosphorus (P), total calcium (Ca), and total protein. Serum
creatinine was measured by automated procedure with the use of
kinetic alkaline picrate assay.21,13 Urinary albumin was measured
only for participants with ages 45–64 years by immunoturbidimetry
preceded by ultra-filtration.20,21 Daily tests were carried out for
external and internal quality control. The intra-assay error in blind
duplicates was o10% for urinary variables and o5% for blood
variables. Trained medical doctors measured blood pressure by
mercury sphygmomanometers22 and administered questionnaires
on cardiovascular disease,23 treatment with drug(s), and previous
diagnoses with inclusion of specific questions on kidney diseases.24
eGFR
Kidney function was indexed by eGFR with the use of 60 ml/
min 1.73 m2 as the threshold for low values.1 The abbreviated
MDRD equation was used for eGFR calculation as it best predicted
true GFR for the methods of the present study as assessed by
analyses of inulin clearance (true GFR) in a separate group not
belonging to the Gubbio population (188 persons with kidney
disease, 140 persons with non-renal diseases, 52 healthy controls;
214 men and 166 women; ages 18–88 years; mean urinary
creatinine¼ 1.033 mg/min).13 Serum creatinine in this group was
measured by the same method and in the same period as for the
Gubbio population. eGFR underestimated true GFR (mean
bias¼6.1%, inter-quartile range¼ 38.9%) and had an accuracy of
0.939 for the prediction of true GFR o60 ml/min 1.73 m2 (sensi-
tivity for true GFR o60 ml/min 1.73 m2¼ 0.953, false-positive
rate¼ 6.9%). The Cockcroft–Gault equation was not used as
estimates by this equation are largely biased in older ages and
overweight,13,14 two traits that are highly prevalent in the Gubbio
cohort as usually in population samples of industrialized coun-
tries.18 Time variability of serum creatinine (and eGFR) was assessed
in a subset of the Gubbio cohort with repeated measures
(correlation coefficients between measures over 6.3-month mean
period 40.8, Po0.001; mean change o1%, P40.3; n¼ 88 men
and 112 women; ages 18–82 years; serum creatinine range
0.53–1.43 mg/100 ml).
The MDRD equation calculates eGFR as 186 serum
creatinine1.154 age0.203, times a factor for female gender
(0.742) and a factor for ethnicity (not used owing to the presence
of white persons only in the Gubbio sample). The 0.742 factor for
female gender slightly underestimates true GFR in white women
independently of GFR.13,14 To control for this possible bias, two
eGFR values were calculated in women: the first value by the original
0.742 factor of the MDRD equation; the second value by a lab-
specific factor designed to eliminate the underestimate found in our
unit for women (0.742þ 13.4% underestimate¼ 0.841). In women
of the separate group with true GFR data, the use of the lab-specific
factor increased the accuracy of eGFR for prediction of true GFR
o60 ml/min 1.73 m2 from 0.946 to 0.958 owing to reduction of
the false-positive rate from 8.2 to 5.1%.
Other definitions
Laboratory data, blood pressure, and questionnaires were used to
define the presence of six disorders potentially secondary to kidney
dysfunction: (1) high serum uric acid; (2) high serum P and/or low
serum Ca; (3) high serum K; (4) anemia; (5) hypertension; and (6)
cardiovascular disease. Serum concentration was defined as high for
values in the highest 10% of the gender-specific distribution in the
Gubbio cohort and, for uric acid, also as a reported drug treatment
for high uric acid. Thresholds were identical in men and women for
definition of high serum P (44.1 mg/100 ml) and high serum K
(44.6 mmol/L), higher in men than women for definition of high
serum uric acid (47.0 and 45.4 mg/100 ml). Serum total Ca
normalized per 7 g of serum protein was used to reduce the
confounding of albumin and globulins on definition of low serum
Ca.25 The threshold for definition of low normalized serum Ca was
identical in men and women (lowest 10% of the gender-specific
distribution: o8.6 mg/100 ml). Anemia was defined as blood
hemoglobin o12 g/100 ml in men and post-menopausal women,
as blood hemoglobin o11 g/100 ml in women with menses.26
Hypertension was defined as systolic pressureX140 mm Hg and/or
diastolic pressure X90 mm Hg and/or reported drug treatment for
hypertension. Cardiovascular disease was defined by questionnaires
on cerebrovascular disease (stroke or transient ischemic attack),
coronary heart disease (myocardial infarction or angina), claudica-
tio, and heart failure.23 Urinary creatinine excretion was used as
index of creatinine generation (muscular creatinine release and
dietary creatinine intake).27 Urinary albumin was defined as elevated
when X20 mg/min.20 The urinary albumin/creatinine ratio was not
used in analysis to avoid the confounding of body mass.22 Three
indices were used to evaluate awareness and control of kidney
disease: reported kidney disease, reported antihypertensive treat-
ment, and hypertension control. Reported kidney disease was
defined as a previous diagnosis of kidney disease (acute or chronic,
excluding stone disease), of kidney failure (acute or chronic), or of
nephrectomy. Hypertension treatment was defined as drug treat-
ment for hypertension, hypertension control as systolic/diastolic
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pressure o140/90 mm Hg in persons on drug treatment for
hypertension.
Statistics
Statistical procedures included simple correlation analysis, w2
analysis, McNemar’s test for paired categorical data, analysis of
variance, logistic regression analysis, calculation of odds ratio, and
of 95% CI. Data are reported as mean7s.d., unless otherwise
indicated. The gender-specific age distribution in the adult Italian
population was used for estimates of the prevalence of eGFR
o60 ml/min 1.73 m2 in the general Italian population (age X18
years at the 1999 National Census: n¼ 22.7 million of men and 24.7
million of women).
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